465 Studies Now Enrolling
A Phase 1b Study Evaluating the Safety and Pharmacology of Atezolizumab (ANTIPD-L1 Antibody) Administered in Combination with Immunomodulatory Agents in Patients with Acute Myeloid Leukemia
A study for patients with Acute Myeloid Leukemia (AML) using study drug atezolizumab and guadecitabine
| Sponsor: | Hoffmann-La Roche |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ9045 |
| U.S. Govt. ID: | NCT02892318 |
| Contact: | Joseph Jurcic: 646-314-5077 / jgj2110@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to test the safety of the combination of the experimental drugs called atezolizumab and guadecitabine (not yet approved by the U.S. Food and Drug Administration FDA or any other regulatory authority outside the United States) to find out what effects, good or bad, the combination of atezolizumab and guadecitabine has on patients with
This study is closed
